112 related articles for article (PubMed ID: 33548629)
1. Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.
Yang B; Ke W; Wan Y; Li T
Biochem Biophys Res Commun; 2021 Mar; 545():89-97. PubMed ID: 33548629
[TBL] [Abstract][Full Text] [Related]
2. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
[TBL] [Abstract][Full Text] [Related]
3. PGK1 facilities cisplatin chemoresistance by triggering HSP90/ERK pathway mediated DNA repair and methylation in endometrial endometrioid adenocarcinoma.
Zhou JW; Tang JJ; Sun W; Wang H
Mol Med; 2019 Mar; 25(1):11. PubMed ID: 30925862
[TBL] [Abstract][Full Text] [Related]
4. Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.
Gentilin E; Minoia M; Bondanelli M; Tagliati F; Degli Uberti EC; Zatelli MC
Endocrine; 2017 Jun; 56(3):621-632. PubMed ID: 27585662
[TBL] [Abstract][Full Text] [Related]
5. Corilagin Inhibits Esophageal Squamous Cell Carcinoma by Inducing DNA Damage and Down-Regulation of RNF8.
Qiu F; Liu L; Lin Y; Yang Z; Qiu F
Anticancer Agents Med Chem; 2019; 19(8):1021-1028. PubMed ID: 30848215
[TBL] [Abstract][Full Text] [Related]
6. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
Yang S; Wang XQ
BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
[TBL] [Abstract][Full Text] [Related]
7. Therapeutically blocking Interleukin-11 Receptor-α enhances doxorubicin cytotoxicity in high grade type I endometrioid tumours.
Winship A; Van Sinderen M; Rainczuk K; Dimitriadis E
Oncotarget; 2017 Apr; 8(14):22716-22729. PubMed ID: 28186993
[TBL] [Abstract][Full Text] [Related]
8. Exonuclease 1 (Exo1) Participates in Mammalian Non-Homologous End Joining and Contributes to Drug Resistance in Ovarian Cancer.
He D; Li T; Sheng M; Yang B
Med Sci Monit; 2020 Mar; 26():e918751. PubMed ID: 32167078
[TBL] [Abstract][Full Text] [Related]
9. Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells.
Girouard J; Lafleur MJ; Parent S; Leblanc V; Asselin E
Gynecol Oncol; 2013 Feb; 128(2):335-43. PubMed ID: 23174537
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
11. Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy.
Ding K; Yuan Y; Chong QY; Yang Y; Li R; Li X; Kong X; Qian P; Xiong Z; Pandey V; Ma L; Wu Z; Lobie PE; Zhu T
Endocrinology; 2017 Jun; 158(6):1595-1611. PubMed ID: 28204229
[TBL] [Abstract][Full Text] [Related]
12. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.
Chon HS; Marchion DC; Xiong Y; Chen N; Bicaku E; Stickles XB; Bou Zgheib N; Judson PL; Hakam A; Gonzalez-Bosquet J; Wenham RM; Apte SM; Lancaster JM
Gynecol Oncol; 2012 Jan; 124(1):119-24. PubMed ID: 22032837
[TBL] [Abstract][Full Text] [Related]
13. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
Zhang X; Kyo S; Nakamura M; Mizumoto Y; Maida Y; Bono Y; Takakura M; Fujiwara H
Cancer Lett; 2014 Apr; 345(1):106-14. PubMed ID: 24333732
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
Bai L; Wang A; Zhang Y; Xu X; Zhang X
Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
[TBL] [Abstract][Full Text] [Related]
15. Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: a novel therapeutic target.
Asaka R; Miyamoto T; Yamada Y; Ando H; Mvunta DH; Kobara H; Shiozawa T
Lab Invest; 2015 Dec; 95(12):1363-73. PubMed ID: 26367491
[TBL] [Abstract][Full Text] [Related]
16. MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.
Li Y; Zhang S; Wang Y; Peng J; Fang F; Yang X
BMC Cancer; 2018 Dec; 18(1):1294. PubMed ID: 30594176
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
18. Rad18 and Rnf8 facilitate homologous recombination by two distinct mechanisms, promoting Rad51 focus formation and suppressing the toxic effect of nonhomologous end joining.
Kobayashi S; Kasaishi Y; Nakada S; Takagi T; Era S; Motegi A; Chiu RK; Takeda S; Hirota K
Oncogene; 2015 Aug; 34(33):4403-11. PubMed ID: 25417706
[TBL] [Abstract][Full Text] [Related]
19. Effect of altered WIG-1 expression on DDP sensitivity in a DDP-resistant esophageal squamous cancer cell line.
Qiu Y; Zou YB; Li K; Jiang YG; Yang K; Zhao YP; Guo W
Curr Cancer Drug Targets; 2012 Oct; 12(8):950-61. PubMed ID: 22794122
[TBL] [Abstract][Full Text] [Related]
20. Met Signaling Cascade Is Amplified by the Recruitment of Phosphorylated Met to Lipid Rafts via CD24 and Leads to Drug Resistance in Endometrial Cancer Cell Lines.
Ono YJ; Tanabe A; Tanaka T; Tanaka Y; Hayashi M; Terai Y; Ohmichi M
Mol Cancer Ther; 2015 Oct; 14(10):2353-63. PubMed ID: 26227486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
